|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||7.50 - 7.50|
|52 Week Range||4.89 - 10.00|
|PE Ratio (TTM)||84.27|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
In a landmark case, the US Food and Drug Administration (FDA) has begun a review of an innovative drug developed for patients who carry a rare genetic blood disorder known as erythropoietic protoporphyria (EPP). EPP patients suffer extreme biochemical reactions when they expose their skin to any light source, particularly the spectrum of visible light, restricting their ability to function properly and forcing them to lead an isolated life in the dark. The pharmaceutical innovation – known as SCENESSE® or afamelanotide 16mg – was developed for EPP over the past 14 years by the Australian pharmaceutical company CLINUVEL.
Understanding Clinuvel Pharmaceuticals Limited’s (ASX:CUV) performance as a company requires examining more than earnings from one point in time. Today I will take you through a basic sense check toRead More...
Clinuvel Pharmaceuticals Limited (ASX:CUV) is currently trading at a trailing P/E of 78.9x, which is higher than the industry average of 28x. While CUV might seem like a stock toRead More...
Clinuvel Pharmaceuticals Limited (ASX:CUV) delivered an ROE of 21.93% over the past 12 months, which is an impressive feat relative to its industry average of 17.87% during the same period.Read More...